Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONAL Platform Trial Start-Ig domain in hematological malignancy
ACTRN12624000964516Phase 3Recruiting
- Sponsor
- Monash University
- Start
- May 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trimethoprim + sulfamethoxazole, doxycycline, immune globulin and subcuvia in hypogammaglobulinemia and infection prophylaxis in hematological malignancy (2 arms), sponsored by Monash University. Primary endpoint: Event-free survival. Started May 2025; status: recruiting.
02
Drugs
trimethoprim + sulfamethoxazoledoxycyclineimmune globulinsubcuvia
03
Conditions
hypogammaglobulinemiainfection prophylaxis in hematological malignancy
Beyond the preview
Go deeper on ACTRN12624000964516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000964516.